Lycera Corp.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2006-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.lycera.com
Clinical Trials
6
Active:0
Completed:4
Trial Phases
2 Phases
Phase 1:3
Phase 2:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (50.0%)Phase 2
3 (50.0%)Study of LYC-55716 With Pembrolizumab in Adult Subjects With Non-Small Cell Lung Cancer
- First Posted Date
- 2018-01-11
- Last Posted Date
- 2019-09-25
- Lead Sponsor
- Lycera Corp.
- Target Recruit Count
- 17
- Registration Number
- NCT03396497
- Locations
- 🇺🇸
Lycera Investigational Site, Seattle, Washington, United States
Study of LYC-55716 in Adult Subjects With Locally Advanced or Metastatic Cancer
Phase 1
Completed
- Conditions
- Cancer
- Interventions
- Drug: LYC-55716
- First Posted Date
- 2016-10-11
- Last Posted Date
- 2019-09-25
- Lead Sponsor
- Lycera Corp.
- Target Recruit Count
- 119
- Registration Number
- NCT02929862
- Locations
- 🇺🇸
Lycera Investigational Site, Fairfax, Virginia, United States
An Efficacy and Safety Study of LYC-30937-EC in Subjects With Moderate Chronic Plaque-type Psoriasis
Phase 2
Completed
- Conditions
- Psoriasis
- Interventions
- Drug: Placebo
- First Posted Date
- 2016-08-19
- Last Posted Date
- 2019-04-10
- Lead Sponsor
- Lycera Corp.
- Target Recruit Count
- 33
- Registration Number
- NCT02872285
- Locations
- 🇺🇸
Lycera Investigational Site, Norfolk, Virginia, United States
Safety and Pharmacokinetic Study of LYC-30937 in Subjects With Active Ulcerative Colitis
- First Posted Date
- 2016-06-29
- Last Posted Date
- 2016-12-14
- Lead Sponsor
- Lycera Corp.
- Target Recruit Count
- 6
- Registration Number
- NCT02818543
- Locations
- 🇭🇺
DRC Ltd., Balatonfured, Hungary
🇭🇺PRA Magyarorszag Kft, Budapest, Hungary
Open-label Extension Study to Assess Safety and Tolerability of LYC-30937-EC in Subjects With Active Ulcerative Colitis
- First Posted Date
- 2016-05-06
- Last Posted Date
- 2019-03-27
- Lead Sponsor
- Lycera Corp.
- Target Recruit Count
- 112
- Registration Number
- NCT02764229
- Locations
- 🇷🇸
Lycera Investigational Site, Zrenjanin, Serbia
🇺🇸Lycera investigational site, San Antonio, Texas, United States
- Prev
- 1
- 2
- Next
News
No news found